However, the association between the APOC3 promoter polymorphism and NAFLD was not observed in the Dallas Heart Study, in which a cohort of more African Americans with older age and higher BMI were studied[22]. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.